stoxline Quote Chart Rank Option Currency Glossary
Albireo Pharma, Inc. (ALBO)
44.15  0 (0%)    03-02 16:00
Open: 44.9
High: 44.9
Volume: 1,236,106
Pre. Close: 44.15
Low: 44
Market Cap: 916(M)
Technical analysis
2023-03-31 4:16:38 PM
Short term     
Mid term     
Targets 6-month :  51.96 1-year :  52.82
Resists First :  44.49 Second :  45.22
Pivot price 44.04
Supports First :  43.3 Second :  36.02
MAs MA(5) :  44.18 MA(20) :  44.18
MA(100) :  29.73 MA(250) :  26.39
MACD MACD :  1.2 Signal :  1.7
%K %D K(14,3) :  68.5 D(3) :  64.2
RSI RSI(14): 68
52-week High :  45.22 Low :  16.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ALBO ] has closed below upper band by 42.0%. Bollinger Bands are 84.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 44.78 - 45 45 - 45.15
Low: 43.41 - 43.71 43.71 - 43.9
Close: 43.82 - 44.27 44.27 - 44.56
Company Description

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Headline News

Fri, 14 Jun 2024
Biodel Announces Adjournment of Annual Meeting until Thursday, October 27, Urges Stockholders to Vote -

Fri, 14 Jun 2024
ALBO - Albireo Reports Second Quarter 2019 Financial Results -

Thu, 02 Feb 2023
Buyout From Ipsen: Do Not Underestimate Value Of Albireo's Contingent Value Right - Seeking Alpha

Mon, 09 Jan 2023
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline - Yahoo Finance

Wed, 19 May 2021
Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition - StockTitan

Wed, 19 Jun 2019
Albireo And Odevixibat In Orphan Pediatric Cholestatic Liver Diseases: Making Magnificent Progress (NASDAQ:ALBO ... - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 21 (M)
Shares Float 14 (M)
Held by Insiders 3.6 (%)
Held by Institutions 107.6 (%)
Shares Short 554 (K)
Shares Short P.Month 823 (K)
Stock Financials
EPS -6.66
EPS Est Next Qtrly -0.92
EPS Est This Year -3.65
EPS Est Next Year -3.45
Book Value (p.s.) 4.84
Profit Margin -228.6 %
Operating Margin -214.8 %
Return on Assets (ttm) -25 %
Return on Equity (ttm) -93.1 %
Qtrly Rev. Growth 168.3 %
Gross Profit (p.s.) 1.89
Sales Per Share 2.76
EBITDA (p.s.) -5.93
Qtrly Earnings Growth 0 %
Operating Cash Flow -115 (M)
Levered Free Cash Flow -74 (M)
Stock Valuations
PE Ratio -6.63
PEG Ratio 0
Price to Book value 9.12
Price to Sales 15.95
Price to Cash Flow -7.95
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-11-03
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android